UniProtKB/Swiss-Prot P02545 : Variant p.Arg401Cys
Prelamin-A/C
Gene: LMNA
Feedback ?
Variant information
Variant position:
401
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Arginine (R) to Cysteine (C) at position 401 (R401C, p.Arg401Cys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from large size and basic (R) to medium size and polar (C)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In EDMD2; abnormal nuclear localization in a honeycomb expression pattern in about 22% of cultured skin fibroblasts from heterozygous patients; enhances the interaction with SYNE2; no effect on nuclear localization; no effect on protein level.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
401
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
664
The length of the canonical sequence.
Location on the sequence:
EGEEERLRLSPSPTSQRSRG
R ASSHSSQTQGGGSVTKKRKL
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human EGEEERLRLSPSPTSQRSRGR ASSHSSQTQGGGSVTKKRKL
Mouse EGEEERLRLSPSPTSQRSRGR ASSHSSQSQGGGSVTKKRKL
Rat EGEEERLRLSPSPTSQRSRGR ASSHSSQSQGGGSVTKKRKL
Pig EGEEERLRLSPSPTSQRSRGR ASSHSSQTQSGGSVTKKRKL
Chicken EGEEERLRLSPSPSSQRG--- ARSSGLQHSGAGS-AKKRRL
Xenopus laevis EGEEERLRLSPSPNTQKRSAR TIASHSGAHISSSASKRRRL
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 661
Prelamin-A/C
Chain
1 – 646
Lamin-A/C
Region
384 – 664
Tail
Region
384 – 442
Disordered
Compositional bias
391 – 417
Polar residues
Modified residue
390 – 390
Phosphoserine
Modified residue
392 – 392
Phosphoserine; by CDK1
Modified residue
395 – 395
Phosphoserine; by ATR
Modified residue
398 – 398
Phosphoserine
Modified residue
403 – 403
Phosphoserine
Modified residue
404 – 404
Phosphoserine
Modified residue
406 – 406
Phosphoserine
Modified residue
407 – 407
Phosphoserine
Modified residue
414 – 414
Phosphoserine
Modified residue
416 – 416
Phosphothreonine
Modified residue
417 – 417
N6-acetyllysine
Cross
417 – 417
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)
Cross
420 – 420
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)
Mutagenesis
381 – 381
E -> K. Impaired lamin assembly.
Mutagenesis
384 – 384
E -> K. Impaired lamin assembly.
Mutagenesis
386 – 386
R -> M. Loss of interaction with IFFO1.
Mutagenesis
386 – 386
R -> VLP. Impaired lamin assembly.
Mutagenesis
390 – 390
S -> A. Decreased localization to the nucleoplasm during interphase.
Mutagenesis
392 – 392
S -> A. Impaired disassembly of the nuclear envelope during mitosis. Strongly decreased disassembly of the nuclear envelope during mitosis; when associates with A-22. Decreased localization to the nucleoplasm during interphase. Impaired disassembly of the micronuclear envelope in response to genome instability.
Mutagenesis
392 – 392
S -> D. Mimics phosphorylation; increased localization to the nucleoplasm during interphase. Causes redistribution between the nucleus and the cytoplasm during interphase; when associated with D-22 and D-628.
Mutagenesis
395 – 395
S -> A. Impaired phosphorylation by ATR in response to genome instability leading ro decreased phosphorylation by CDK1.
Mutagenesis
395 – 395
S -> D. Mimics phosphorylation; disassembly of the micronuclear envelope in response to genome instability.
Literature citations
Frequent low penetrance mutations in the Lamin A/C gene, causing Emery Dreifuss muscular dystrophy.
Vytopil M.; Ricci E.; Dello Russo A.; Hanisch F.; Neudecker S.; Zierz S.; Ricotti R.; Demay L.; Richard P.; Wehnert M.; Bonne G.; Merlini L.; Toniolo D.;
Neuromuscul. Disord. 12:958-963(2002)
Cited for: VARIANTS EDMD2 LYS-32 DEL; ASN-63; GLN-336; GLN-343 AND CYS-401;
Nuclear envelope alterations in fibroblasts from patients with muscular dystrophy, cardiomyopathy, and partial lipodystrophy carrying lamin A/C gene mutations.
Muchir A.; Medioni J.; Laluc M.; Massart C.; Arimura T.; van der Kooi A.J.; Desguerre I.; Mayer M.; Ferrer X.; Briault S.; Hirano M.; Worman H.J.; Mallet A.; Wehnert M.; Schwartz K.; Bonne G.;
Muscle Nerve 30:444-450(2004)
Cited for: SUBCELLULAR LOCATION; CHARACTERIZATION OF VARIANTS EDMD2 LYS-32 DEL; SER-63; GLN-249; LYS-358; CYS-401; TRP-453 AND PRO-527; CHARACTERIZATION OF VARIANTS EDMD2 LYS-208 DEL AND HIS-377; CHARACTERIZATION OF VARIANT FPLD2 LEU-482; CHARACTERIZATION OF VARIANT CMD1A CYS-541;
Mutations in LMNA modulate the lamin A--Nesprin-2 interaction and cause LINC complex alterations.
Yang L.; Munck M.; Swamvdinathan K.; Kapinos L.E.; Noegel A.A.; Neumann S.;
PLoS ONE 8:E71850-E71850(2013)
Cited for: CHARACTERIZATION OF VARIANTS CYS-401; ASP-411; CYS-413; ILE-415; CYS-419; PRO-421 AND GLY-427; INTERACTION WITH SYNE2;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.